Concepedia

Ayumi Kaneda

AK

Statistics

Publications

5

Citations

217

H-Index

5

Active since

2011

Affiliations

Kyowa Kirin (Japan)(Current)

Aichi Cancer Center

Keio University

Ayumi Kaneda is an author at Kyowa Kirin (Japan) specializing in molecular oncology, pharmacology, and oncology.

Publications per year

2011–2022

5

Publications

5

The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma.

Ayumi Kaneda, Toshihiro Seike, Tomohiro Danjo et al. · PubMed · 2020 · 148 citations · Full text

Life Sciences, Molecular Biology, Oncology +16

Inhibition of macrophage activation and suppression of graft rejection by DTCM-glutarimide, a novel piperidine derived from the antibiotic 9-methylstreptimidone

Masatoshi Takeiri, Miyuki Tachibana, Ayumi Kaneda et al. · Inflammation Research · 2011 · 32 citations

Life Sciences, Immunology, Pharmacology +17

Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial

Hiroji Iwata, Rikiya Nakamura, Norikazu Masuda et al. · Japanese Journal of Clinical Oncology · 2022 · 15 citations · Full text

Medicine, Oncology, Pharmacology +17

Inhibition of RANKL- and LPS-induced osteoclast differentiations by novel NF-κB inhibitor DTCM-glutarimide

Naoki Koide, Ayumi Kaneda, Takashi Yokochi et al. · International Immunopharmacology · 2015 · 11 citations

Medicine, Cell Biology, Pharmacology +11

Abstract 3086: Discovery of a <i>first-in-class</i> TEAD inhibitor which directly inhibits YAP/TAZ-TEAD protein-protein interaction and shows a potent anti-tumor effect in malignant pleural mesothelioma

Ayumi Kaneda, Toshihiro Seike, Takeshi Uemori et al. · Cancer Research · 2019 · 11 citations

Medicine, Oncology, Pharmacology +17

1–5 of 5